syncing guidelines- catanzaro
TRANSCRIPT
Guideline Summary: Guideline Summary: When to Start ARTWhen to Start ART
Guidelines for the Use of Antiretroviral Agents
in Adults and Adolescents
Andy Catanzaro, MD
Infectious Diseases
March 2012
OutlineOutline
Overview of HIV therapy Initiation of Therapy Special Issues
October 2011 www.aidsetc.org2
HIV TermsHIV Terms
October 20113 www.aidsetc.org
HIV Terms/Acronyms
ART: Antiretroviral Therapy
HIV Viral Load: amount of virus in the blood
Undetectable Viral Load: Goal of Therapy
CD4 Count: Immune Marker
Genotype: Sensitivity of the Virus to Medications
Goal of HIV Therapy: Stop the Virus!
October 2011 www.aidsetc.org
What are ‘The Guidelines’ for HIV Therapy
Independent panel of experts
Review Current Literature on HIV
Make Recommendations
Strength of Evidence given for each guidance
(www.aidsinfo.nih.gov)
What the Guidelines AddressWhat the Guidelines Address
Baseline evaluation Laboratory testing When to initiate & change therapy Therapeutic options ART-associated adverse effects
6
What the Guidelines AddressWhat the Guidelines Address
Treatment of acute HIV infection Special considerations (pregnant,
injection drug users, coinfected with HBV, HCV, or TB)
Preventing secondary transmission
7
Websites to Access the GuidelinesWebsites to Access the Guidelines
http://aidsinfo.nih.gov http://www.aidsetc.org
8
Goals of TreatmentGoals of Treatment
Improve quality of life Reduce HIV-related morbidity and mortality Restore and/or preserve immunologic
function Suppress HIV viral load Prevent HIV transmission
9
Use of CD4 Cell Levels to Guide Use of CD4 Cell Levels to Guide Therapy DecisionsTherapy Decisions
CD4 count The major indicator of immune function Most recent CD4 count is best predictor of
disease progression A key factor in decision to start prophylaxis Important in determining response to ART
Adequate response: CD4 increase 50-150 cells/µL per year
*
10
Studies in patients CD4>500Studies in patients CD4>500
Favor Treatment NA-ACCORD
Neutral on Treatment ART-CC CASCADE
11
ART in Treatment Recommended for ART in Treatment Recommended for All PatientsAll Patients
CD4 count Strength of the Recommendation
Evidence for the Recommendation
<350 Strong Data from randomized clinical trials
350-500 Strong Data from non-randomized clinical trials
>500 Moderate Expert Opinion
12
Use of HIV RNA Levels to Guide Use of HIV RNA Levels to Guide Therapy DecisionsTherapy Decisions
HIV RNA May influence choice of ART Critical in monitoring response to ART
Goal of ART: HIV RNA below limit of detection (ie, <20-75 copies/mL, depending on assay)
13
Use of HIV RNA Levels to Guide Use of HIV RNA Levels to Guide Therapy Decisions Therapy Decisions (2)(2)
RNA monitoring Check at baseline Before initiating ART 2-4 weeks (not more than 8 weeks) after start or change of
ART, then every 4-8 weeks until suppressed to <200 copies/mL
Every 3-4 months with stable patients; may consider every 6 months for stable adherent patients with VL suppression >2-3 years
Isolated “blips” may occur (transient low-level RNA, typically <400 copies/mL), are not thought to predict virologic failure
ACTG defines virologic failure as confirmed HIV RNA >200 copies/mL
14
When to Start ARTWhen to Start ART
Potent ART may improve and preserve immunefunction in most patients with virologic suppression, regardless of baseline CD4 count ART indicated for all with low CD4 count or symptoms Earlier ART may result in better immunologic responses
and better clinical outcomes Reduction in AIDS- and non-AIDS-associated morbidity and
mortality Reduction in HIV-associated inflammation and associated
complications
Reduction in HIV transmission
Recommended ARV combinations are considered to bedurable and tolerable
15
When to Start ARTWhen to Start ART
Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts
Current recommendation: ART for all patients with CD4 Randomized control trial (RTC) data support benefit of ART if
CD4 count 350 cells/µL No RTC data on benefit of ART at CD4 counts of >350 cells/µL,
but observational cohort data exist
Currently available ARVs are effective and well tolerated
16
Potential Benefits of Early Therapy Potential Benefits of Early Therapy (CD4 count >500 cells/µL)(CD4 count >500 cells/µL)
Cohort study data show survival benefit if ART initiated at CD4 count >500 cells/µL
Earlier ART may prevent HIV-related end organ damage; deferred ART may not reliably repair damage acquired earlier Increasing evidence of direct HIV effects on various
end organs and indirect effects via HIV-associated inflammation
End organ damage occurs at all stages of infection
17
Potential Benefits of Early Therapy Potential Benefits of Early Therapy (CD4 count >500 cells/µL) (CD4 count >500 cells/µL) (2)(2)
Potential decrease in risk of many complications, including: HIV-associated nephropathy Liver disease progression from hepatitis B or
hepatitis C Cardiovascular disease Malignancies (AIDS defining and non-AIDS defining) Neurocognitive decline Blunted immunological response owing to ART
initiation at older age Persistent T-cell activation and inflammation
18
Potential Benefits of Early Therapy Potential Benefits of Early Therapy (CD4 count >500 cells/µL) (CD4 count >500 cells/µL) (3)(3)
Prevention of sexual and blood borne transmission of HIV
Prevention of mother-to-child transmission of HIV
Prevention of transmission to a sexual partner
19
Potential Limitations of Early TherapyPotential Limitations of Early Therapy (CD4 count >500 cells/µL)(CD4 count >500 cells/µL)
ARV-related toxicities Drug resistance Non-adherence to ART Cost
20
Recommendations for Initiating ART Recommendations for Initiating ART (3)(3)
Patients may choose to postpone ART Providers may elect to defer ART, based on
patients’ clinical or psychosocial factors caveat: do we really know who is ready?
21
Consider More Rapid Initiation of ART Consider More Rapid Initiation of ART (e.g. before the genotype is available)(e.g. before the genotype is available)
Pregnancy Acute opportunistic infection Lower CD4 count (eg, <200 cells/µL) Rapid decline in CD4 Higher viral load HIV Associated Nephropathy HBV coinfection when HBV treatment is indicated
22
Consider Deferral of ARTConsider Deferral of ART
Clinical or personal factors may support deferral of ART If CD4 count is low, deferral should be considered
only in unusual situations, and with close follow-up
When there are significant barriers to adherence If comorbidities complicate or prohibit ART “Elite controllers” and long-term nonprogressors
23
Initial ART Regimens: DHHS CategoriesInitial ART Regimens: DHHS Categories Preferred
Randomized controlled trials show optimal efficacy and durability
Favorable tolerability and toxicity profiles
24
Initial Treatment: Choosing RegimensInitial Treatment: Choosing Regimens
3 main categories: 1 Non-nucleoside Reductase Inhibitor + 2 Nucleside
Reductase Inhibitor (NRTI) 1 Protease Inhibitor + 2 NRTIs 1 Integrase Inhibitor + 2 NRTIs
Combinations preferred for most patients (Bias: Once Daily Preferred by patients)
25
Initial Therapy: Fixed Dose CombinationsInitial Therapy: Fixed Dose Combinations
Preferred:TDF/FTC(Truvada)
Once-daily dosing High virologic efficacy Active against HBV Potential for renal toxicity
Alternative:ABC/3TC(Epzicom)
Once-daily dosing Risk of hypersensitivity reaction if positive for
HLA-B*5701 Possible inferior efficacy if baseline HIV RNA
>100,000 copies/mL Active against HBV
Acceptable:ZDV/3TC(Combivir)
Twice-daily dosing Preferred for pregnant women More toxicities than TDF/FTC or ABC/3TC
26
Initial Regimens: PreferredInitial Regimens: Preferred
NNRTI based EFV/TDF/FTC (Atripla) 1,
Protease Inhibitor based
ATV/r (Reyataz/Norvir) + TDF/FTC (Truvada)DRV/r (Prezista/Norvir) + TDF/FTC (Truvada)²
Integrase Inhibitor based
RAL (Isentress BID) + TDF/FTC (Truvada)
Pregnant women LPV/r (Kaletra BID) + ZDV/3TC (Combivir)²
1. EFV should not be used during the first trimester of pregnancy or in women trying to conceive or not using effective and consistent contraception.27
October 2011 www.aidsetc.org
Drug-Drug Interactions
Too Common
Always check new medications
Resources: Guidelines, Uptodate, Epocrates
Websites to Access the GuidelinesWebsites to Access the Guidelines
http://www.aidsetc.org http://aidsinfo.nih.gov
29